Predict your next investment

Marengo Therapeutics company logo
HEALTHCARE | Drug Development
marengotx.com

See what CB Insights has to offer

Stage

Series A | Alive

Total Raised

$39M

Last Raised

$39M | 4 yrs ago

About Marengo Therapeutics

Marengo Therapeutics, an ATP company, is developing the next generation of T cell immune engagers that activate and expand a novel population of “superkiller” T cells. Marengo antibodies induce potent and durable anti-tumor responses in refractory solid tumor models and promote protective tumor immunity (“immune memory”) while triggering less pro-inflammatory cytokine release than anti-CD3 T cell engagers. Marengo’s lead project, a first- and -best-in-class therapy with single agent potential, is progressing to IND for PD1-refractory solid tumors. The company’s advanced antibody discovery platform has also generated a pipeline of multi-specific antibody therapies with potential in multiple tumor types.

Marengo Therapeutics Headquarter Location

Riverside Technology Center 840 Memorial Drive 4th Floor

Cambridge, Massachusetts, 02139,

United States

617-917-4980

Latest Marengo Therapeutics News

07:30 ET Immunitas Therapeutics Appoints Seng-Lai 'Thomas' Tan, Ph.D. as Chief Scientific Officer

Sep 8, 2021

Company expands leadership with biotech veteran with deep immunology expertise following $58 million Series B financing News provided by Share this article Share this article WALTHAM, Mass., Sept. 8, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, has appointed Seng-Lai "Thomas" Tan, Ph.D., as Chief Scientific Officer. Dr. Tan brings over 20 years of therapeutic research experience in both large and small biopharmaceutical settings across different disease areas, including infectious disease, autoimmunity, and oncology. He also has broad expertise in various modalities spanning small molecules, monoclonal and bispecific antibodies, and cell-penetrating peptides. "Thomas' extensive track record in drug development will be an extraordinary asset for the company," said Jeffrey Goldberg, President and Chief Executive Officer of Immunitas. "With Thomas joining the team, coupled with our recent financing, Immunitas will continue to build on the solid foundation that has been created over the last two years, expanding our pipeline and driving drugs into the clinic to help patients in need." Prior to joining Immunitas, Dr. Tan served as Chief Scientific Officer at Bicara Therapeutics. Previously, he was Vice President, Head of Immunology at Elstar Therapeutics, now Marengo Therapeutics, where he devised and implemented effective strategies to build a portfolio of differentiated and high value projects in immuno-oncology. He also has led several projects toward discovery and clinical development at Forma Therapeutics and EMD Serono Research and Development Institute. Dr. Tan holds a doctorate in microbiology (viral immunology) from the University of Washington School of Medicine. "Immunitas' combined approaches of human immunology and high-dimensional computational data analysis have uniquely positioned the company in immuno-oncology with a pipeline of differentiated programs focused on novel biological pathways," said Dr. Tan. "I am eager to collaborate with the Immunitas team to achieve the mission of providing new treatment options for patients living with cancer by quickly advancing our programs from discovery to translation and move these powerful therapies into the clinic." The appointment follows the recent $58 million Series B financing and a series of leadership and executive management expansions in August, including Amanda Wagner as Chief Business Officer and Geeta Vemuri, Agent Capital, and Brian Halak, on behalf of Medical Excellence Capital (MEC), to the Immunitas Board of Directors. About Immunitas Therapeutics Immunitas is a single cell genomics-based therapeutics company focused on immunology that is advancing multiple programs to the clinic. Immunitas' programs are derived from their platform, a cross-functional, highly integrated, single cell genomics approach that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class NK and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. Immunitas is also advancing IMT-073, a dual-target NK and T cell modulator. The company was founded by Longwood Fund with leading scientists from Dana-Farber, MGH, the Broad, and MIT. Since being founded in 2019, Immunitas has raised a total of $97 million in venture funding from a strong syndicate of investors including Agent Capital, Longwood Fund, Medical Excellence Capital, Alexandria Venture Investment, Evotec, Leaps by Bayer, M Ventures and Novartis Venture Fund. To learn more, visit www.immunitastx.com . SOURCE Immunitas Therapeutics, Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Marengo Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Marengo Therapeutics is included in 3 Expert Collections, including Cancer Therapeutics.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Marengo Therapeutics Patents

Marengo Therapeutics has filed 6 patents.

The 3 most popular patent topics include:

  • Monoclonal antibodies
  • Immune system
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/7/2018

Clusters of differentiation, Cytokines, Monoclonal antibodies, Chemokine receptors, Interleukins

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/7/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Cytokines, Monoclonal antibodies, Chemokine receptors, Interleukins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Application

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Marengo Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Marengo Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.